← Library
PT-141 (Research Grade)
Research Use
Also known as Palatin precursor
Function
Primary
Sexual dysfunction (men & women) · Libido enhancement
Mechanism
MC3R/MC4R agonist — centrally activates hypothalamic melanocortin pathways; enhances sexual arousal independent of hormonal levels.
Evidence
Pre-clinical / Observational
Research
Phase II/III data led to Vyleesi approval
Dosing
Range
0.5–2 mg PRN
Frequency
As needed (max 1×/24h)
Route
Subcutaneous · Intranasal
Administration & Technique
Subcutaneous
45–60 min before activity.
DeviceInsulin syringe.
TechniqueAbdomen or thigh. Rotate sites.
Intranasal
Research alternative — faster onset (~30 min).
DeviceNasal spray.
Technique1 spray per nostril.
Injection & Application Sites
Front
Back
Subcutaneous
- Abdomen — 2 in (5 cm) away from the navel, either side. Fastest, most consistent SubQ absorption.
- Outer thigh — Upper outer quadrant, a hand-width below the hip. SubQ pinch at 45°.
Intranasal
- Intranasal — Alternate nostrils, spray on inhalation, do not sniff hard.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
PRN only.
Timing & Interactions
When to take
SubQ or intranasal 45–60 min before anticipated activity. Max ~1 dose per 24 hrs.
Do not combine with
- ·Uncontrolled hypertension
- ·Melanotan II — same class
Complements
- ·Kisspeptin-10 for research stacks
Storage & Reconstitution
Powder (Pre-Reconstitution)
Refrigerate 2–8°C; freeze for long-term.
After Reconstitution
Refrigerated up to 4 weeks with bacteriostatic water.
Reconstitution Calculator
Concentration
2.50 mg/mL
Volume per dose
0.100 mL
Insulin syringe
10.0 units (U-100)
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Your Notes
Sign in to save personal notes on PT-141 (Research Grade) and sync them to Vial Lab.
Benefits
- ·On-demand libido enhancement in both sexes
- ·Centrally mediated, hormone-independent
Risks
- ·Nausea
- ·Flushing
- ·Transient BP elevation
- ·Compounded purity concerns
Contraindications
- ·Uncontrolled hypertension
- ·Cardiovascular disease
Regulatory
Research-grade not FDA-approved; FDA-approved analog = Vyleesi (bremelanotide)
Veterinary Use (Pets)
No established veterinary protocol for PT-141 (Research Grade). Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Functional Groups
Cited Works
- Diamond LE et al. PT-141, a melanocortin agonist for sexual dysfunction. Int J Impot Res. 2004;16:51.